Quick Answer
Tarsus Pharmaceuticals, Inc. reported Operating Income Loss of -$70.97 million for the year ending 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +41.1% in Operating Income Loss from 2024 to 2025.
- This data is from Tarsus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$633.0 thousand | Q1 2020: -$2.12 million | Q2 2020: -$3.26 million | Q3 2020: -$10.14 million | Q1 2021: $10.71 million | Q2 2021: $7.28 million | Q3 2021: -$15.71 million | Q1 2022: -$19.52 million | Q2 2022: -$5.22 million | Q3 2022: -$22.91 million | Q1 2023: -$24.95 million | Q2 2023: -$32.82 million | Q3 2023: -$40.94 million | Q1 2024: -$37.68 million | Q2 2024: -$33.30 million | Q3 2024: -$25.16 million | Q1 2025: -$26.28 million | Q2 2025: -$22.18 million | Q3 2025: -$14.53 million.
- Over the full 7 years of available data (2019 to 2025), Tarsus Pharmaceuticals, Inc.'s Operating Income Loss has declined by 1,551.2%.
- Historical annual values: Fiscal year 2025: -$70.97 million | Fiscal year 2024: -$120.57 million | Fiscal year 2023: -$143.16 million | Fiscal year 2022: -$62.71 million | Fiscal year 2021: -$12.16 million | Fiscal year 2020: -$27.00 million | Fiscal year 2019: -$4.30 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: